Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652 | Terminated Phase 1 Results

• 5 other identifiers: CDR0000597410P30CA069533OHSU-HEM-07156-LIRB#4101GENZYME-OHSU-HEM-07156-L
• Study Type: interventional
• Target: 2
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving clofarabine together with rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine when given together with rituximab and to see how well they work in treating patients with relapsed B-cell non-Hodgkin lymphoma.

Conditions

Lymphoma

Keywords

extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue; nodal marginal zone B-cell lymphoma; splenic marginal zone lymphoma; recurrent adult Burkitt lymphoma; recurrent adult diffuse large cell lymphoma; recurrent adult diffuse mixed cell lymphoma; recurrent adult diffuse small cleaved cell lymphoma; recurrent adult grade III lymphomatoid granulomatosis; recurrent adult immunoblastic large cell lymphoma; recurrent adult lymphoblastic lymphoma; recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; recurrent grade 3 follicular lymphoma; recurrent mantle cell lymphoma; recurrent marginal zone lymphoma; recurrent small lymphocytic lymphoma; cutaneous B-cell non-Hodgkin lymphoma

Outcome Measures

Primary Outcomes (2)

• The Maximum Tolerated Dose (MTD) of Oral Clofarabine in Adult Patients With Relapsed CD20+ Non-Hodgkin Lymphoma(NHL)

  Initially, 3 patients will be enrolled into a dose level during the dose-escalation portion: * If no patient experiences dose-limiting toxicities during the first 4 weeks, then 3 patients will be enrolled into the next dose level. * If one of the three patients develops dose-limiting toxicities, then 3 additional patients will be enrolled in that cohort. If none of the additional 3 patients experiences dose-limiting toxicities, then further dose-escalation occurs. * If one additional patient experiences dose-limiting toxicities, then the maximum tolerated dose is exceeded.

  14 days for up to 8 cycles (1 cycle equals 14 days on drug, 14 days off drug) for a total of up to 224 days

• Estimate Objective Response Rates of Oral Clofarabine in Combination With Rituximab in Relapsed CD20+NHL

  Oral Clofarabine x 14 days for up to 8 cycles (1 cycle equals 14 days on drug, 14 days off drug) for a total of up to 224 days AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle

Secondary Outcomes (5)

• Determine One-year Progression Free Survival Using the MTD of Clofarabine With Rituximab in Relapsed CD20+NHL

  One year after study drug(s) have been given. Duration of study up to 1 year.

• Determine the Safety and Efficacy of Clofarabine in Combination With Rituximab

  Duration of the study, up to 1 year.

• Whether Clofarabine Acts as an Inhibitor of DNA Methylation Similar to Cladribine by Performing Scientific Correlates

  Duration of the study, up to 1 year.

• Whether Response to Clofarabine Alone or in Combination With Rituximab Correlates With Changes in Global Serum DNA Methylation Index

  Duration of the study, up to 1 year.

• Identity of the Gene Activated by Clofarabine Therapy by Using Genomic DNA and RNA Array Technology

  Twice monthly at standard of care visits for 3 months post last cycle of chemotherapy.

Study Arms (1)

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

EXPERIMENTAL

Phase I: Oral Clofarabine x 14 days for up to 8 cycles at assigned dose level below (1 cycle equals 14 days on drug, 14 days off). Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV Dose Level 1: 2 mg Dose Level 2: 4 mg Dose Level 3: 6 mg Phase II: Oral Clofarabine x 14 days for up to 8 cycles (Dose determined from phase I) AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV

Biological: rituximab; Drug: clofarabine; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis

Interventions

rituximab BIOLOGICAL

Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

clofarabine DRUG

Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

DNA methylation analysis GENETIC

We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

gene expression analysis GENETIC

Total RNA will be processed for determination of gene expression by microarray

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

microarray analysis GENETIC

we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals \<\< 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

polymerase chain reaction GENETIC

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

high performance liquid chromatography OTHER

Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

laboratory biomarker analysis OTHER

50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).

Also known as: High Performance Liquid Chromatography (HPLC)

Oral Clofarabine + Rituximab in Relapsed B Cell NHL

Eligibility Criteria

• Age: 18 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed B-cell lymphoma * Relapsed disease * CD20-positive disease * Must have had bone marrow aspiration and biopsy (uni- or bilateral) within the past 42 days and chest CT and CT of the abdomen and pelvis within the past 28 days * Documented bidimensionally measurable disease within the past 28 days * Patients with non-measurable disease in addition to measurable disease must have all non-measurable disease assessed within 42 days prior to registration PATIENT CHARACTERISTICS: * Eastern Cooperative Oncology Group(ECOG) performance status 0-2 * Leukocyte count ≥ 3,000/μL * Absolute neutrophil count ≥ 1,500/μL * Platelet count ≥ 75,000/μL * Total bilirubin ≤ 2 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 6 months after completion of study therapy * No known AIDS or HIV-associated complex * No active hepatitis B infection * No other severe concurrent disease, history of serious organ dysfunction, or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment * No uncontrolled systemic fungal, bacterial, viral, or other infection, defined as ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment * No history of intolerance or allergic reactions to clofarabine or rituximab * No significant concurrent disease, illness, or psychiatric disorder that would compromise the patient's safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results * No concurrent active GI disease that may impair absorption of oral clofarabine PRIOR CONCURRENT THERAPY: * Recovered from all previous therapies * No prior gastrointestinal (GI) surgery that may impair absorption of oral clofarabine * More than 2 weeks since prior and no concurrent anticancer therapy, except for hydroxyurea * More than 4 weeks since prior radioimmunotherapy * More than 1 month since prior investigational agents * No concurrent cytotoxic therapy or investigational therapy * No other concurrent investigational or commercial agents or therapies administered with the intent to treat the patient's malignancy * No concurrent alternative medications (e.g., herbal or botanical for anticancer purposes) * No other concurrent chemotherapy or immunotherapy * No concurrent radiotherapy * No concurrent colony stimulating factors (phase I portion of the study)

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• OHSU Knight Cancer Institute: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Knight Cancer Institute at Oregon Health and Science University

Portland, Oregon, 97239-3098, United States

Location

MeSH Terms

Conditions

Lymphoma; Lymphoma, B-Cell, Marginal Zone; Burkitt Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Immunoblastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

Rituximab; Clofarabine; DNA Methylation; Gene Expression Profiling; Microarray Analysis; Polymerase Chain Reaction; Chromatography, High Pressure Liquid

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, B-Cell; Epstein-Barr Virus Infections; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Leukemia, Lymphoid; Leukemia; Hematologic Diseases; Leukemia, B-Cell; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Murine-Derived; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Adenine Nucleotides; Purine Nucleotides; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Arabinonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Ribonucleotides; Methylation; Alkylation; Biochemical Phenomena; Chemical Phenomena; Metabolism; Genetic Phenomena; Genetic Techniques; Investigative Techniques; Microchip Analytical Procedures; Nucleic Acid Amplification Techniques; Chromatography, Liquid; Chromatography; Chemistry Techniques, Analytical

Results Point of Contact

• Title: Dr. Craig Okada
• Organization: OHSU Knight Cancer Institute

Okadac@ohsu.edu

503-494-1080

Study Officials

• Craig Okada, MD, PhD

  Oregon Health and Science University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2008
• First Posted: June 5, 2008
• Study Start: May 1, 2008
• Primary Completion: January 1, 2009
• Study Completion: April 1, 2009
• Last Updated: November 27, 2019
• Results First Posted: September 16, 2011

Record last verified: 2019-11

Locations

US (1)